RPS6KB1 and inflammatory bowel disease: Currently, there are three classes of extensively studied autophagy modulators as candidates for IBD treatment, including inflammasome inhibitors, gut microbiota modulators, and AMPK-mTOR-p70S6K signaling modulators, which greatly expand the new horizon of autophagy modulation strategies applied to IBD treatment and open up the space for the development of new therapeutic strategies.